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Impact of renal function on the eﬀ ects of LDL cholesterol 
lowering with statin-based regimens: a meta-analysis of 
individual participant data from 28 randomised trials 
Cholesterol Treatment Trialists’ (CTT) Collaboration*
Summary
Background Statin therapy is eﬀ ective for the prevention of coronary heart disease and stroke in patients with mild-to-
moderate chronic kidney disease, but its eﬀ ects in individuals with more advanced disease, particularly those 
undergoing dialysis, are uncertain.
Methods We did a meta-analysis of individual participant data from 28 trials (n=183 419), examining eﬀ ects of statin-
based therapy on major vascular events (major coronary event [non-fatal myocardial infarction or coronary death], 
stroke, or coronary revascularisation) and cause-speciﬁ c mortality. Participants were subdivided into categories of 
estimated glomerular ﬁ ltration rate (eGFR) at baseline. Treatment eﬀ ects were estimated with rate ratio (RR) per 
mmol/L reduction in LDL cholesterol.
Findings Overall, statin-based therapy reduced the risk of a ﬁ rst major vascular event by 21% (RR 0·79, 95% CI 
0·77–0·81; p<0·0001) per mmol/L reduction in LDL cholesterol. Smaller relative eﬀ ects on major vascular events 
were observed as eGFR declined (p=0·008 for trend; RR 0·78, 99% CI 0·75–0·82 for eGFR ≥60 mL/min per 1·73 m²; 
0·76, 0·70–0·81 for eGFR 45 to <60 mL/min per 1·73 m²; 0·85, 0·75–0·96 for eGFR 30 to <45 mL/min per 1·73 m²; 
0·85, 0·71–1·02 for eGFR <30 mL/min per 1·73 m² and not on dialysis; and 0·94, 0·79–1·11 for patients on dialysis). 
Analogous trends by baseline renal function were seen for major coronary events (p=0·01 for trend) and vascular 
mortality (p=0·03 for trend), but there was no signiﬁ cant trend for coronary revascularisation (p=0·90). Reducing 
LDL cholesterol with statin-based therapy had no eﬀ ect on non-vascular mortality, irrespective of eGFR. 
Interpretation Even after allowing for the smaller reductions in LDL cholesterol achieved by patients with more 
advanced chronic kidney disease, and for diﬀ erences in outcome deﬁ nitions between dialysis trials, the relative 
reductions in major vascular events observed with statin-based treatment became smaller as eGFR declined, with 
little evidence of beneﬁ t in patients on dialysis. In patients with chronic kidney disease, statin-based regimens should 
be chosen to maximise the absolute reduction in LDL cholesterol to achieve the largest treatment beneﬁ ts. 
Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, European Community 
Biomed Programme, Australian National Health and Medical Research Council, Australian National Heart Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Statin-based therapy is widely used among patients with 
chronic kidney disease to reduce the risk of atherosclerotic 
events (myocardial infarction and ischaemic stroke), but 
there is uncertainty about the eﬀ ects of such treatment 
among patients with an estimated glomerular ﬁ ltration 
rate (eGFR) below 30 mL/min per 1·73 m². In particular, 
controversy exists over whether patients undergoing 
maintenance dialysis beneﬁ t from statins.1 The ﬁ ndings 
of the 4D2 and AURORA3 trials did not show substantial 
beneﬁ ts of statins on cardiac disease or stroke among 
patients undergoing haemodialysis, and no independently 
signiﬁ cant beneﬁ t was observed among the subgroup of 
patients undergoing dialysis treatment in the SHARP 
study.4 Systematic reviews and meta-analyses of trials 
among patients with chronic kidney disease have reached 
conﬂ icting conclusions about the eﬀ ects of statin therapy 
among individuals on dialysis.5–14 The Kidney Disease 
Improving Global Outcomes (KDIGO) lipid management 
guidelines currently suggest that statin-based therapy 
should be prescribed for selected high-risk patients with 
chronic kidney disease, but should not be initiated in 
individuals who already need dialysis.15 
Meta-analyses published up to now have several 
limitations.5–14 First, in a meta-analysis of individual 
participant data from large trials of statins,16 the relative 
eﬀ ects of statin therapy on major vascular events in a wide 
range of patients were proportional to the absolute 
magnitude of the reduction in LDL cholesterol. Smaller 
relative decreases in risk among people on dialysis might 
occur if the absolute reduction in LDL cholesterol achieved 
among them was smaller than the equivalent reduction 
among those not on dialysis. Indeed, in the SHARP trial,4 
smaller relative reductions in risk were reported in patients 
on dialysis as a result of diminished compliance and lower 
baseline LDL cholesterol. However, the extent to which 
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variations in absolute reductions in LDL cholesterol 
account for the results of trials in patients on dialysis has 
not been investigated. Second, trial ﬁ ndings show that 
statin therapy does not reduce the risk of non-
atherosclerotic cardiac mortality (eg, cardiac arrhythmia, 
heart failure);17,18 therefore, an apparent lack of eﬃ  cacy in 
patients on dialysis might have arisen if some non-
atherosclerotic deaths were mistakenly attributed to 
coronary heart disease. Diﬀ erences were recorded in the 
deﬁ nitions used in the primary outcomes in the 4D, 
AURORA, and SHARP trials,2–4 and the proportions of 
patients on dialysis who were coded as dying from a 
coronary cause also varied (appendix p 2). Thus, further 
investigation is needed to assess the extent to which these 
diﬀ erences aﬀ ected the ﬁ ndings of previous meta-analyses.
The Cholesterol Treatment Trialists’ (CTT) Collaboration 
database incorporates individual parti ci pant data from 
trials of statin regimens into which at least 1000 participants 
were recruited and followed up for at least 2 years.16 The 
database includes two trials of statin therapy among 
patients on dialysis (4D and AURORA) and one among 
individuals who had a renal transplant (ALERT).2,3,19 To this 
database, we added individual participant data from the 
SHARP trial of simvastatin plus ezetimibe versus placebo 
among 9270 patients with chronic kidney disease 
(including 3025 patients on dialysis).4 By applying 
consistent outcome categorisation across these renal 
trials,3 we aimed to compare the eﬀ ects of statin-based 
therapy on major vascular events at diﬀ erent levels of renal 
function more reliably than has previously been possible. 
Methods
Study design and patients
The methods of the CTT Collaboration have been 
described previously.16,20–22 In brief, in 1994, we established 
a collaborative meta-analysis of individual participant 
data from all trials of statin-based regimens in which at 
least 1000 patients were followed up for 2 years or longer. 
We achieved data completeness through electronic 
literature searches and regular enquiry of researchers 
and statin manufacturers, with data requested promptly 
when we identiﬁ ed new trials.
Procedures
During the planning of the analyses, we identiﬁ ed major 
diﬀ erences in the proportions of cardiac deaths attributed 
to coronary heart disease in the AURORA trial3 compared 
with other trials of statin-based regimens among patients 
on dialysis.2,4 On further enquiry with the AURORA 
investigators, we established that the outcome 
adjudication rules in that trial diﬀ ered substantially from 
those used in the 4D and SHARP trials. In particular, in 
AURORA, a death of uncertain cause was attributed to 
coronary heart disease if, as was frequently the case, 
there was a previous history of coronary heart disease, 
whereas in 4D and SHARP, which had broadly similar 
adjudication rules, deaths were attributed to coronary 
heart disease only if there was strong evidence that 
coronary atherosclerosis was the cause (appendix p 3). 
To ensure that deaths were coded as uniformly as 
possible within this meta-analysis, we readjudicated all 
deaths in the AURORA trial before analysis of the 
combined data. The SHARP trial coding rules for deaths 
were applied by independent clinicians (MDS, PBM, and 
AGJ) at the University of Glasgow’s Institute of 
Cardiovascular and Medical Sciences (Glasgow, UK), 
who had full access to the AURORA trial source data 
and, for all participants, were unaware of both the 
original adjudicated outcome and the treatment 
allocation. The result of this process was that the 
proportion of deaths attributed to coronary heart disease 
in patients on dialysis in the AURORA trial fell from 32% 
Research in context
Evidence before this study
Systematic reviews and tabular meta-analyses to investigate 
the eﬀ ects of statin-based therapy on vascular risk among 
patients with chronic kidney disease, have reached conﬂ icting 
conclusions about the eﬀ ects of statins in patients on dialysis. 
These studies have not taken into account between-trial 
diﬀ erences in achieved LDL cholesterol reduction and variations 
in the deﬁ nition of coronary death.
Added value of this study
Individual participant data for our meta-analysis were available 
from the Cholesterol Treatment Trialists’ Collaboration 
database, which has near-complete information on baseline 
renal function, LDL cholesterol measurements, and subtypes of 
major vascular events. Furthermore, we included data from the 
SHARP trial and readjudicated deaths from the AURORA trial. 
Our meta-analysis provides a more reliable summary than 
previous tabular meta-analyses of the eﬀ ects of statin-based 
therapy on vascular risk among people with diﬀ erent stages of 
chronic kidney disease.
Implications of all the available evidence
Lowering LDL cholesterol with a statin-based regimen 
eﬀ ectively reduces vascular risk among patients with 
mild-to-moderate chronic kidney disease. However, even after 
allowing for both outcome adjudication diﬀ erences and smaller 
reductions in LDL cholesterol as the estimated glomerular 
ﬁ ltration rate declines, there is a trend towards smaller relative 
risk reductions for a given absolute reduction in LDL cholesterol 
in both major coronary events and strokes in patients with 
more advanced chronic kidney disease (with little evidence of 
beneﬁ t in patients on dialysis). In patients with chronic kidney 
disease, statin-based regimens achieving larger reductions in 
LDL cholesterol are likely to achieve larger reductions in 
cardiovascular risk. 
See Online for appendix
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to 8% (compared with 11% in 4D and 8% in SHARP), 
and the proportion of other cardiac deaths in patients on 
dialysis rose from 5% to 23% (compared with 33% in 4D 
and 19% in SHARP; appendix p 2). 
Outcomes and statistical analysis
The main outcomes of our meta-analysis are major 
vascular events, deﬁ ned as major coronary events 
(ie, non-fatal myocardial infarction or death from 
coronary heart disease), coronary revascularisation, or 
stroke; and mortality, subdivided into vascular and non-
vascular causes. We subdivided all participants, 
including those with a functioning kidney transplant, 
by baseline renal function using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI)23 
equation for eGFR. We used the following categories of 
eGFR: 60 mL/min per 1·73 m² or greater; 45 mL/min 
per 1·73 m² to less than 60 mL/min per 1·73 m²; 
30 mL/min per 1·73 m² to less than 45 mL/min 
per 1·73 m²; less than 30 mL/min per 1·73 m² and 
not on dialysis; or receiving dialysis (haemodialysis 
or peritoneal dialysis) at randomisation. We used 
Cox proportional-hazard models analogous to those 
reported previously,21 but using the readjudicated 
AURORA data and categories of baseline renal function 
as an additional independent variable, to model the 
5-year baseline risk of major vascular events among 
patients allocated to either control or less intensive 
statin therapy (appendix pp 4–6). On the basis of these 
risk prediction models, we categorised participants into 
one of three baseline 5-year risk categories for major 
vascular events (<20%, 20% to <30%, or ≥30%). 
Analyses of treatment eﬀ ect were done according to the 
intention-to-treat principle—ie, they included all 
participants, irrespective of whether they received their 
allocated treatment. Analyses of the eﬀ ects of statin-
based regimens on outcome rates within each included 
trial were derived from the log-rank (o–e) statistic and its 
variance (v) for ﬁ rst events. Findings of a previous CTT 
meta-analysis showed that the principal source of 
between-trial heterogeneity in the eﬀ ects of statins on 
major vascular events is the size of the diﬀ erences in the 
achieved absolute LDL cholesterol reduction at 1 year (d).16 
Therefore, as previously described,16,20,21 we ﬁ rst standar d-
ised the average log event rate ratio (RR) for each trial 
(derived from the o–e statistic and v) to correspond to an 
eﬀ ect per 1·0 mmol/L (39 mg/dL) reduction in LDL 
cholesterol, and then we combined the standardised 
results in a meta-analysis, with weights proportional to 
the amount of statistical information (ie, inverse-variance 
weighting). Speciﬁ cally, we calculated the log RR per 
mmol/L as S/V with variance 1/V (yielding a 95% CI 
S/V ± 1·96/√V), where S is the sum over all trials of d(o–e) 
and V is the sum over all trials of d2v. For subgroup 
analyses in diﬀ erent categories of baseline renal function, 
the weight for each trial was generally the absolute 
diﬀ erence in LDL cholesterol recorded for the whole 
trial, apart from in SHARP (the only trial to enrol patients 
with chronic kidney disease both on dialysis and not on 
dialysis), for which separate dialysis and non-dialysis 
subgroup-speciﬁ c weights were used, since the LDL 
cholesterol diﬀ erence diﬀ ered substantially between 
these subgroups (appendix p 7).4
We decided a priori not to calculate absolute treatment 
eﬀ ects directly from available trials, since we noted that 
the underlying vascular risks in the trials contributing 
patients to each category of eGFR were determined 
principally by factors unrelated to kidney function and, 
hence, absolute risk reductions would not be 
generalisable. For example, trials contributing data for 
patients with mild or no chronic kidney disease were 
done mainly in patients with a previous history of 
coronary heart disease who were, therefore, at high risk, 
whereas data for patients with chronic kidney disease not 
on dialysis came mainly from the SHARP trial,4 which 
excluded patients with previous coronary heart disease. 
Instead, we aimed to calculate RRs per 1·0 mmol/L at 
diﬀ erent levels of eGFR, which can be applied to 
contemporaneous and region-speciﬁ c event rates to 
calculate the absolute eﬀ ects of treatment.
In the forest plots, we show 95% CIs only with summary 
RRs; all other RRs are presented with 99% CIs to allow for 
multiple hypothesis testing in subgroup analyses. 
We compared RRs per mmol/L reduction in LDL 
cholesterol in diﬀ erent categories of baseline renal function 
and of risk of major vascular events using χ² tests for trend. 
In sensitivity analyses, we recalculated trend tests after 
excluding patients on dialysis, to assess whether any 
positive ﬁ ndings were dependent on results in this category. 
We did the statistical analyses using SAS version 9.3 and 
R version 2.11.1.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
WGH, JE, BM, LB, and CB had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
At the time of the present analysis (May 11, 2016), 
individual participant data had been provided from 
28 trials with 183 419 participants,2–4,17–19,24–45 including all 
trials in renal populations.2–4,19 Data were unavailable for 
three trials: one trial of atorvastatin versus placebo in 
4731 patients with a history of cerebrovascular disease;46 
one trial of atorvastatin versus usual care in 1600 patients 
with coronary heart disease;47 and one trial of simvastatin 
plus ezetimibe versus placebo in 1873 patients with aortic 
stenosis.48 Less than 1% of participants in these trials had 
a baseline eGFR below 30 mL/min per 1·73 m².48–50
In 23 trials, a statin-based regimen was compared 
with control (143 807 participants; mean baseline 
LDL cholesterol 3·64 [SD 0·92] mmol/L; mean diﬀ erence 
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in LDL cholesterol at 1 year –1·08 mmol/L; median 
follow-up 4·8 years).2–4,17–19,24–40 In the other ﬁ ve trials, 
an intensive statin regimen was assessed against a 
standard statin regimen (39 612 participants; mean 
baseline LDL cholesterol 2·53 [SD 0·63] mmol/L; mean 
diﬀ erence in LDL cholesterol at 1 year –0·51 mmol/L; 
median follow-up 5·1 years).41–45 Overall, the mean age of 
participants was 62·6 years (SD 9·6), 133 229 (73%) 
patients were men, 105 517 (58%) had vascular disease, 
and 35 781 (20%) had diabetes (table). 
Data for baseline renal function were available for 
181 032 (99%) participants: 123 560 (68%) people had an 
eGFR of 60 mL/min per 1·73 m² or greater; 34 417 (19%) 
had an eGFR of 45 mL/min per 1·73 m² to less than 
60 mL/min per 1·73 m²; 10 634 (6%) had an eGFR of 
30 mL/min per 1·73 m² to less than 45 mL/min per 1·73 m²; 
5368 (3%) had an eGFR less than 30 mL/min per 1·73 m² 
and were not on dialysis; and 7053 (4%) were on dialysis 
(6557 haemodialysis and 496 peritoneal dialysis) at 
randomisation (table). Patients from the SHARP trial 
Baseline renal function* All patients 
(n=183 419)
eGFR ≥60 mL/min 
per 1·73m2 
(n=123 560)
eGFR 45 to 
<60 mL/min 
per 1·73m2 
(n=34 417)
eGFR 30 to 
<45 mL/min 
per 1·73m2 
(n=10 634)
eGFR <30 mL/min 
per 1·73m2, not on 
dialysis (n=5368)
On dialysis 
(n=7053)
Demographic characteristics
Age (years) 60·7 (9·0) 67·4 (8·1) 69·3 (10·1) 64·2 (12·3) 62·2 (10·5) 62·6 (9·6)
Men 94 770 (77%) 23 111 (67%) 6500 (61%) 3008 (56%) 4318 (61%) 133 229 (73%)
Women 28 790 (23%) 11 306 (33%) 4134 (39%) 2360 (44%) 2735 (39%) 50 190 (27%)
Current smokers 25 970 (21%) 5183 (15%) 1444 (14%) 641 (12%) 1009 (14%) 34 896 (19%)
Renal function
eGFR (mL/min per 1·73 m2) 79 (13) 54 (4) 39 (4) 20 (7) NA 69 (19)
Functioning kidney 
transplant†
500 (<1%) 668 (2%) 613 (6%) 247 (5%) NA 2102 (1%)
Disease history
Diabetes 22 306 (19%) 6599 (19%) 2444 (23%) 1265 (24%) 2654 (38%) 35 781 (20%)
Coronary heart disease 64 027 (52%) 19 650 (57%) 5518 (52%) 850 (16%) 1383 (20%) 92 591 (50%)
Other vascular disease 7396 (6%) 2559 (7%) 1134 (11%) 612 (11%) 1099 (16%) 12 926 (7%)
No history of vascular disease 52 137 (42%) 12 208 (35%) 3982 (37%) 3906 (73%) 4571 (65%) 77 902 (42%)
Blood pressure
Treated hypertension 57 281 (47%) 20 390 (60%) 7609 (72%) 4491 (84%) 5357 (76%) 96 354 (53%)
Systolic blood pressure 
(mm Hg)
137·7 (20·6) 140·7 (21·9) 140·4 (22·8) 139·7 (21·9) 139·1 (24·0) 138·6 (21·2)
Diastolic blood pressure 
(mm Hg)
81·4 (11·2) 80·5 (11·3) 79·4 (11·9) 79·3 (12·5) 76·6 (12·7) 80·9 (11·4)
Physical measurements
BMI (kg/m2) 27·7 (4·7) 27·7 (4·5) 27·6 (4·8) 27·2 (5·4) 26·2 (5·4) 27·6 (4·8)
Lipid measurements
Total cholesterol (mmol/L) 5·38 (1·08) 5·33 (1·05) 5·43 (1·17) 5·56 (1·31) 4·89 (1·22) 5·36 (1·08)
LDL cholesterol (mmol/L) 3·36 (0·96) 3·30 (0·93) 3·33 (0·99) 2·98 (0·96) 2·70 (0·90) 3·31 (0·96)
HDL cholesterol (mmol/L) 1·17 (0·36) 1·17 (0·35) 1·16 (0·36) 1·14 (0·35) 1·08 (0·38) 1·17 (0·36)
Triglycerides (mmol/L) 1·78 (1·02) 1·83 (1·00) 2·03 (1·21) 2·24 (1·42) 2·21 (1·66) 1·83 (1·08)
Risk of major vascular event
5-year risk <20% 86 273 (70%) 17 975 (52%) 4887 (46%) 3772 (70%) 3503 (50%) 117 900 (64%)
5-year risk 20% to <30% 26 971 (22%) 11 021 (32%) 2998 (28%) 888 (17%) 1511 (21%) 43 758 (24%)
5-year risk ≥30% 10 316 (8%) 5421 (16%) 2749 (26%) 708 (13%) 2039 (29%) 21 761 (12%)
Follow-up (years)
Median (IQR) follow up 
among survivors‡
4·9 (4·5–5·3) 4·9 (4·5–5·4) 4·9 (4·5–5·4) 4·9 (4·5–5·4) 4·7 (3·9–5·4) 4·9 (4·4–5·3)
Data are mean (SD) for continuous variables and number of participants (%) for categorical variables, unless otherwise stated. eGFR=estimated glomerular ﬁ ltration rate 
(calculated with the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula). NA=not applicable. BMI=body-mass index. *Data from 2387 participants 
without a baseline creatinine measurement contribute only to the All patients column. †All participants with a functioning transplant were from the ALERT trial (appendix 
p 8). ‡Median follow-up among survivors weighted by trial-speciﬁ c variances of observed log-rank (o–e) for major vascular events. 
Table: Baseline characteristics of participants, by renal function
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accounted for about four-ﬁ fths of those with an eGFR less 
than 30 mL/min per 1·73 m² and not on dialysis at 
randomisation, but for only about a ﬁ fth of patients with 
an eGFR of 30 mL/min per 1·73 m² to less than 
45 mL/min per 1·73 m², with trials among elderly people,33 
patients with heart failure,17,18 and the Heart Protection 
Study31 accounting for a large proportion of the remainder 
(appendix p 8). 
Compared with patients with an eGFR of at least 
60 mL/min per 1·73 m², a larger proportion of individuals 
with an eGFR less than 30 mL/min per 1·73 m² (whether 
on dialysis or not) had diabetes and a smaller proportion 
had vascular disease (mainly because people with a 
deﬁ nite history of coronary heart disease were excluded 
from the SHARP trial). Compared with patients with 
an eGFR of at least 30 mL/min per 1·73 m², those with 
eGFR less than 30 mL/min per 1·73 m² (including those 
on dialysis) also had lower concentrations of LDL 
cholesterol and HDL cholesterol, and higher concen-
trations of triglycerides at randomisation (table; 
appendix p 8). After adjustment for the particular trial 
into which a patient had been recruited, and for other 
prognostic variables, decreased eGFR was associated 
independently with an increased risk of major vascular 
events (appendix pp 5, 6). 
Overall, statin-based treatment reduced the risk of a 
ﬁ rst major vascular event by 21% (RR 0·79, 95% CI 
0·77–0·81; p<0·0001) per mmol/L reduction in LDL 
cholesterol, including reduced risks of major coronary 
events (0·76, 0·73–0·79) and stroke (0·84, 0·80–0·89; 
Figure 1: Eﬀ ects on major vascular events per mmol/L reduction in LDL cholesterol, by baseline renal function
Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 
95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular ﬁ ltration rate. RR=rate ratio.
Major coronary event
eGFR ≥60 mL/min per 1·73 m²
eGFR 45 to <60 mL/min per 1·73 m²
eGFR 30 to <45 mL/min per 1·73 m²
eGFR <30 mL/min per 1·73 m² not on dialysis
On dialysis
Total
Coronary revascularisation
eGFR ≥60 mL/min per 1·73 m²
eGFR 45 to <60 mL/min per 1·73 m²
eGFR 30 to <45 mL/min per 1·73 m²
eGFR <30 mL/min per 1·73 m² not on dialysis
On dialysis
Total
Stroke
eGFR ≥60 mL/min per 1·73 m²
eGFR 45 to <60 mL/min per 1·73 m²
eGF 30 to <45 mL/min per 1·73 m²
eGFR <30 mL/min per 1·73 m² not on dialysis
On dialysis
Total
Major vascular event
eGFR ≥60 mL/min per 1·73 m²
eGFR 45 to <60 mL/min per 1·73 m²
eGFR 30 to <45 mL/min per 1·73 m²
eGFR <30 mL/min per 1·73 m² not on dialysis
On dialysis
Total
RR (CI) per 1·0 mmol/L 
reduction in LDL 
cholesterol
p for 
trend
Statin or more
intensive regimen
Control or less
intensive regimen
Number of events (% per annum)
3200 (1·2%)
1157 (1·7%)
457 (2·3%)
163 (1·5%)
264 (2·1%)
5303 (1·4%)
3943 (1·5%)
1039 (1·5%)
265 (1·3%)
99 (0·9%)
183 (1·5%)
5618 (1·5%)
1408 (0·5%)
575 (0·8%)
263 (1·3%)
116 (1·1%)
213 (1·7%)
2591 (0·7%)
7348 (2·9%)
2377 (3·6%)
863 (4·5%)
320 (3·0%)
571 (4·7%)
11 617 (3·2%)
4178 (1·6%)
1479 (2·2%)
567 (2·8%)
179 (1·7%)
287 (2·3%)
6761 (1·8%)
4963 (1·9%)
1387 (2·1%)
328 (1·6%)
123 (1·2%)
224 (1·8%)
7113 (1·9%)
1661 (0·6%)
708 (1·0%)
284 (1·4%)
137 (1·3%)
199 (1·6%)
3019 (0·8%)
8933 (3·6%)
3013 (4·6%)
1014 (5·2%)
364 (3·5%)
599 (5·0%)
 14 079 (3·9%)
0·74 (0·70–0·79)
0·76 (0·69–0·84)
0·80 (0·68–0·95)
0·87 (0·68–1·12)
0·89 (0·70–1·14)
0·76 (CI 0·73−0·79)
0·76 (0·71–0·80)
0·71 (0·64–0·80)
0·81 (0·64–1·02)
0·78 (0·57–1·05)
0·78 (0·58–1·05)
0·75 (0·73−0·78)
0·83 (0·76–0·92)
0·81 (0·70–0·93)
0·91 (0·73–1·13)
0·83 (0·63–1·10)
1·09 (0·82–1·44)
0·84 (0·80−0·89)
0·78 (0·75–0·82)
0·76 (0·70–0·81)
0·85 (0·75–0·96)
0·85 (0·71–1·02)
0·94 (0·79–1·11)
0·79 (0·77−0·81)
0·01
0·9
0·07
0·008
0·5 0·75 1·0 1·5
LDL cholesterol
lowering worse
LDL cholesterol
lowering better
99% or 95% CI
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ﬁ gure 1). There was a signiﬁ cant trend towards smaller 
proportional eﬀ ects on major vascular events with lower 
eGFR at randomisation (p=0·008 for trend). Within each 
baseline renal function category, the proportional 
reduction in major vascular events was similar, 
irrespective of estimated cardiovascular risk level (all 
trend p values >0·05; appendix p 9). The trend towards 
smaller proportional eﬀ ects on major vascular events 
with lower eGFR was attributable chieﬂ y to major 
coronary events (p=0·01 for trend) and stroke (p=0·07 for 
trend; ﬁ gure 1). The trend in proportional eﬀ ects 
observed for major coronary events resulted from 
combining non-fatal myocardial infarction (p=0·06 for 
trend) and coronary mortality (p=0·2 for trend; ﬁ gure 2). 
Overall, statin-based treatment reduced the need for 
coronary revascularisation procedures by 25% (RR 0·75, 
95% CI 0·73–0·78, p<0·0001) per mmol/L LDL 
cholesterol reduction (ﬁ gure 1); however, no trend by 
baseline renal function was observed for this outcome 
(p=0·9 for trend).
The risk of vascular death was reduced overall by 12% 
(RR 0·88, 95% CI 0·85–0·91; p<0·0001) per mmol/L 
reduction in LDL cholesterol (ﬁ gure 3), and there was a 
signiﬁ cant trend towards smaller proportional eﬀ ects 
on vascular mortality with worse baseline renal function 
(p=0·03 for trend). However, reducing LDL cholesterol 
with statin-based therapy had no signiﬁ cant eﬀ ect on 
non-vascular mortality at any level of renal function. 
A signiﬁ cant trend towards smaller eﬀ ects on all-cause 
mortality was seen with lower eGFR (p=0·03 for trend; 
ﬁ gure 3). In sensitivity analyses, in which we excluded 
patients undergoing dialysis at randomisation, no 
signiﬁ cant trends were recorded in RRs (per mmol/L 
LDL cholesterol reduction) for vascular outcomes 
(major coronary events, stroke, coronary revascular-
isation, major vascular events) or deaths across eGFR 
categories (all trend p values >0·05; appendix pp 10, 11).
Discussion
There has been considerable uncertainty about the 
cardiovascular eﬀ ects of reducing LDL cholesterol in 
patients with advanced chronic kidney disease, 
particularly those on dialysis, with previous meta-
analyses of published data reaching conﬂ icting 
conclusions.1,5–15 Availability of individual participant data 
from 28 trials of statin-based therapy in patients with 
various degrees of renal impairment, and readjudication 
of all deaths in the AURORA trial,3 has allowed us to 
overcome many of the limitations of previous meta-
analyses.5–14 Our results show that, even after allowing for 
somewhat smaller reductions in LDL cholesterol as GFR 
declines, there is a trend towards smaller relative risk 
reductions for major coronary events and strokes. 
In particular, there was little evidence that statin-based 
therapy was eﬀ ective in patients starting treatment after 
dialysis had been initiated.
Perhaps because several trials of statin-based therapy 
have been done solely among patients on dialysis,2,3 
Figure 2: Eﬀ ects on major coronary events per mmol/L reduction in LDL cholesterol, by baseline renal function
Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 
95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular ﬁ ltration rate. RR=rate ratio.
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1248 (0·5%)
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0·73 (0·68−0·78)
0·72 (0·64−0·82)
0·79 (0·64−0·97)
0·85 (0·62−1·15)
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0·74 (0·71−0·77)
0·77 (0·69–0·86)
0·83 (0·70–0·99)
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 0·06
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0·5 0·75 1·0 1·5
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99% or 95% CI
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treatment guidelines have generally considered the 
evidence among patients not on dialysis separately from 
those on dialysis.15 In our meta-analysis, we looked at 
trends in treatment eﬃ  cacy across all stages of chronic 
kidney disease, including patients on dialysis. Despite 
inclusion of all relevant large-scale trials of statin-based 
therapy among patients with chronic kidney disease, data 
were insuﬃ  cient to be able to diﬀ erentiate reliably between 
a gradual diminution of the relative reductions in risk of 
major vascular events with lower GFR (at least below about 
30 mL/min per 1·73 m²) or a step-wise reduction in 
eﬃ  cacy when a patient commences dialysis. Arguments 
can be made for either interpretation: a gradual diminution 
is predicted by ﬁ ndings of observational studies showing 
weaker associations between LDL cholesterol and 
myocardial infarction among people with impaired renal 
function,51 but if data from dialysis trials were to be 
excluded from our analyses then the relative beneﬁ ts of 
treatment would not diﬀ er signiﬁ cantly among the other 
categories of patients not on dialysis (appendix pp 10, 11).2–4
The pattern of diminished vascular beneﬁ t with lower 
renal function might result, at least partly, from the 
combination of two features that are peculiar to patients 
with chronic kidney disease. First, the proportion of cardiac 
deaths attributable to coronary heart disease—and, hence, 
potentially avoidable by reducing LDL cholesterol—
becomes smaller as eGFR declines.52,53 In our meta-analysis, 
for example, coronary heart disease was the attributed 
cause of 57% of cardiac deaths among individuals with an 
eGFR of 60 mL/min per 1·73 m² or greater, but was the 
cause of only 26% and 27% of such deaths among patients 
with an eGFR less than 30 mL/min per 1·73 m² not on 
dialysis and those on dialysis, respectively (appendix p 2). 
Second, the cause of cardiac deaths (and of non-fatal cardiac 
events) is subject to misclassiﬁ cation because of their 
frequently atypical clinical presentation54 and the diﬃ  culty 
of interpreting raised biomarkers of cardiac damage in 
chronic kidney disease.55,56 
In our meta-analysis, because trial populations were 
highly selected, the event rates in each category of eGFR 
are not a reliable indication of the absolute levels of risks 
that would be seen in the clinic. For example, the SHARP 
study contributed 4201 (78%) of 5368 participants to the 
category with an eGFR less than 30 mL/min per 1·73 m² 
Figure 3: Eﬀ ects on cause-speciﬁ c mortality per mmol/L reduction in LDL cholesterol, by baseline renal function
Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 
95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular ﬁ ltration rate. RR=rate ratio.*Includes 583 deaths from an unknown 
cause in the statin or more intensive regimen group and 653 deaths from an unknown cause in the control or less intensive regimen group. 
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2250 (0·8%)
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4567 (1·7%)
2152 (3·0%)
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0·84 (0·70–1·00)
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and not on dialysis, but, patients with a previous history 
of coronary heart disease were excluded from the trial, so 
the mean risks of major vascular events were lower than 
would be seen in unselected patients with similar eGFRs. 
Conversely, 25 168 (56%) of 45 051 patients with an eGFR 
between 30 mL/min per 1·73 m² and 60 mL/min 
per 1·73 m² had a previous history of coronary heart 
disease (table); thus, the mean risks in these eGFR 
categories were higher than would be expected for 
unselected patients. Previous analyses of the CTT 
database have clearly shown that, across diﬀ erent statin 
regimens, the relative risk reduction is determined 
principally by the absolute reduction in LDL cholesterol 
achieved,16 whereas the ﬁ ndings of the present analysis 
suggest that once GFR is reduced substantially the 
relative eﬀ ects of statins might be smaller. Calculations of 
absolute eﬀ ects on major vascular events are, therefore, 
derived most appropriately from applying GFR-speciﬁ c 
RRs from our meta-analysis to absolute risks reported in 
unselected cohorts of people with chronic kidney disease. 
Results of cohort studies have shown that patients with 
chronic kidney disease are at high risk of atherosclerotic 
disease,57 and in a meta-analysis of such cohorts, every 
30% decrement in eGFR was associated with a 29% 
increase in risk of a major vascular event.58 Therefore, a 
change from an eGFR of 60 mL/min per 1·73 m² to 
10 mL/min per 1·73 m² (a notional threshold for 
commencing dialysis) would correspond to about four 
times the risk. Since there was also a fourfold diﬀ erence 
in relative risk reductions in the corresponding categories 
in our meta-analysis (24% vs 6% per mmol/L reduction in 
LDL cholesterol), the absolute beneﬁ ts of statin-based 
therapy might be of broadly comparable magnitude 
among the wide range of patients with chronic kidney 
disease, even with diminishing relative eﬃ  cacy as eGFR 
falls. The absolute magnitude of any such beneﬁ t, 
however, can vary regionally—eg, there is substantial 
geographical variation in the prevalence of diabetes, a 
major risk factor for vascular disease,59 as a cause of 
chronic kidney disease.60
Despite the relative absence of data from trials of statin-
based therapy in advanced chronic kidney disease, such 
treatment has been shown to be safe with respect to 
adverse events.2–4,13,61 As a result, many nephrologists might 
consider oﬀ ering such treatment to their patients. If so, 
previous results from a CTT meta-analysis16 suggest that 
any beneﬁ ts of such treatment would be increased if larger 
absolute reductions in LDL cholesterol can be achieved. 
Since LDL cholesterol in patients with advanced chronic 
kidney disease is, on average, lower than in other high-
risk populations (table),62 achieving lower concentrations 
of LDL cholesterol would generally require higher-
intensity regimens. However, renal impairment is a risk 
factor for myopathy with high-dose simvastatin,63 and 
other high-dose statin regimens might also pose an 
unacceptable risk of myopathy in patients with advanced 
chronic kidney disease. Since trials have not established 
the safety of atorvastatin 40–80 mg in individuals with an 
eGFR less than 30 mL/min per 1·73 m², the UK’s National 
Institute for Health and Care Excellence (NICE) currently 
recommends atorvastatin 20 mg once daily in populations 
with chronic kidney disease.64 An alternative strategy to 
high-dose statins in patients with chronic kidney disease 
is the combination of a moderate-dose statin with the 
cholesterol absorption inhibitor ezetimibe, which was 
used successfully in the SHARP trial.4 
Although our meta-analysis is strengthened by 
inclusion of near-complete information on the eﬀ ects of 
statin-based therapy on major vascular events at diﬀ erent 
levels of renal function in large trials of statins, it has 
some limitations. The most important limitation is the 
relative paucity of evidence from randomised trials 
among patients with chronic kidney disease compared 
with other high-risk patients. A further limitation is that 
there is no agreed method for determining the precise 
cause or causes of vascular death among patients with 
more advanced chronic kidney disease. Lastly, the CTT 
Collaboration did not request information on adverse 
events other than vascular outcomes, deaths, and cancers 
(cancer data reported elsewhere65), so it is currently not 
possible to study the eﬀ ects of statins on particular 
adverse events (eg, muscle pain) or to investigate statin 
adherence and discontinuations, beyond what has been 
reported by individual trials. The CTT Collaboration is, 
however, currently obtaining the necessary data to do this 
assessment.66 Nevertheless, our meta-analysis does 
provide clear evidence that statin-based therapy was 
beneﬁ cial in a wide range of patients with chronic kidney 
disease and helps to reinforce the important point that 
the beneﬁ ts could be enhanced by using treatments that 
achieve a large absolute reduction in LDL cholesterol in 
such patients. 
In conclusion, previous tabular meta-analyses of 
randomised trials of statin therapy in patients with 
chronic kidney disease could not adjust for diﬀ erences in 
the magnitude of reductions in LDL cholesterol and 
diﬀ erences in the deﬁ nitions of outcomes between trials 
in patients on dialysis. Even after allowing for smaller 
LDL cholesterol reductions achieved among patients 
with more severe chronic kidney disease (particularly 
those already on dialysis), and for outcome adjudication 
diﬀ erences, there was a trend towards smaller reductions 
in major vascular events as eGFR declines.
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